Tesamorelin Significantly Reduces Liver Fat in Adults with MASLD
Background
Metabolic Associated Steatotic Liver Disease (MASLD), previously known as Nonalcoholic Fatty Liver Disease (NAFLD), is a chronic condition characterized by excessive fat accumulation in the liver, affecting a significant portion of the global population. It can progress to more severe forms like Nonalcoholic Steatohepatitis (NASH), leading to inflammation, liver damage, and potentially cirrhosis or liver failure. Currently, there are limited approved pharmacological treatments specifically for MASLD, highlighting a critical unmet medical need. This study aims to evaluate if tesamorelin, a growth hormone-releasing hormone (GHRH) analog, can effectively reduce liver fat in adults with MASLD.
Results
At the 52-week mark, the tesamorelin group demonstrated a significant reduction in liver fat compared to placebo. The mean relative reduction in liver fat, as measured by MRI-PDFF, was 38% in the tesamorelin group versus only 5% in the placebo group (p<0.001). This indicates a robust effect of the treatment. The most impactful finding was that 43% of patients treated with tesamorelin achieved a >30% relative reduction in liver fat, a clinically meaningful threshold associated with improved liver outcomes, compared to just 12% in the placebo group (p<0.0001). Furthermore, tesamorelin treatment led to a 2.5-fold increase in circulating IGF-1 levels, confirming its mechanism of action as a GHRH analog, without significant adverse effects on glucose homeostasis. A subset of patients also showed a 1.8-fold improvement in liver enzyme markers (ALT/AST), suggesting reduced liver inflammation, compared to placebo (p<0.01).
Why It Matters
This study provides compelling evidence that tesamorelin could be a highly effective pharmacological intervention for MASLD, addressing a critical unmet medical need. The significant reduction in liver fat observed suggests a strong potential to halt or even reverse disease progression, particularly in patients at risk of developing NASH. If these positive results are confirmed in larger Phase III trials, tesamorelin could become a groundbreaking, first-in-class treatment option for millions of individuals suffering from MASLD. Future research will focus on evaluating long-term outcomes and its impact on liver fibrosis and overall cardiovascular health.